Detection Rate of Helicobacter Pylori Infection and Atrophic Gastritis Using Serological Markers “GastroPanel®” Among Employees of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Aim: to evaluate, using the “GastroPanel®”, the frequency of detection of H. pylori infection and associated gastric diseases among doctors and medical staff of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow.

Materials and methods. Employees of three branches of the National Medical Research Radiological Centre (n = 434, mean age — 48.5 ± 0.6 years) were examined using laboratory tests “GastroPanel®” (Biohit Oyj, Finland). The test results make it possible to identify infection of the stomach with H. pylori, hypo- and hyperacid conditions, as well as atrophic gastritis of the antrum and body of the stomach, as its precancerous conditions. Esophagogastroduodenoscopy (EGDS) for suspected atrophic gastritis was performed with an Olympus GIF-HQ190 video endoscope (Japan) in a narrow-spectrum mode with close focus (NBI Dual Focus).

Results. The absence of pathological signs detected by “GastroPanel®” was established in 23.3 % of cases, hyperacid state — in 18.4 %, and hypoacid state — in 5.2 %. These disorders are classified as functional. Consequently, the conditional norm in total was identified in 46.9 % of observations. An increased level of antibodies to H. pylori was found in 43.3 % of those examined. Atrophic gastritis in the body of the stomach according to the results of the “GastroPanel®” was detected in 4.8 % of cases (median age — 59 years), in the antrum (or increased secretion of hydrochloric acid) — also in 4.8 % of cases (median age — 52 years). Within two months after laboratory diagnostics, EGDS was performed for 10 out of 15 patients examined at the P. Hertsen Moscow Oncology Research Institute in whom, based on the results of the “GastroPanel®”, the presence of atrophic gastritis in the antrum (or increased secretion of hydrochloric acid) was suspected. In 6 out of 10 cases, atrophic gastritis of the antrum was confirmed (in two of them, the atrophy extended to the body of the stomach and was assessed as severe). Of the 11 people with the “GastroPanel®” conclusion “Atrophic gastritis of the body of the stomach,” an endoscopic examination was carried out in 7 persons, and in all these cases the diagnosis was confirmed, and in two people the conclusion was made of severe atrophic pangastritis.

Conclusion. “GastroPanel®” confirmed its high significance in identifying H. pylori infection and precancerous atrophic changes in the gastric mucosa. Regarding the occupational risks of infection among medical workers, we consider it advisable to conduct such screening without selecting an asymptomatic population.

1. Kaprin A.D., Starinskij V.V., Shahzadova A.O. (eds). Malignant neoplasms in Russia in 2021 (incidence and mortality). Moscow: P. Hertsen Moscow Oncology Research Institute — the Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 2022. (In Russ.)

2. Kaprin A.D., Starinskiy V.V., Shahzadova A.O. (eds). Condition of the oncological help to the population of Russia in 2022. Moscow: P. Hertsen Moscow Oncology Research Institute — the Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 2023. (In Russ.).

3. Conti C.B., Agnesi S., Scaravaglio M., Masseria P., Dinelli M.E., Oldani M., et al. Early gastric cancer: Update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 2023;20(3):2149. DOI: 10.3390/ijerph20032149

4. Moss S.F. The clinical evidence linking Helicobacter pylori to gastric cancer. Cell Mol Gastroenterol Hepatol. 2016;3(2):183–91. DOI: 10.1016/j.jcmgh.2016.12.001

5. Correa P., Piazuelo M.B. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2–9. DOI: 10.1111/j.1751-2980.2011.00550.x

6. Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Abdulkhakov R.A., et al. Treatment of Helicobacter pylori infection: Mainstream and innovations (Literature review and resolution of the Expert Council of the Russian Gastroenterological Association on May 19, 2017). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):4–21. (In Russ.). DOI: 10.22416/1382-4376-2017-27-4-4-21

7. Devyatko A.O., Noskova T.A., Shevchenko N.V. Experience of using the test system «GASTROPANEL» in the preventive medical examination of workforce in JSC RZD. Materialy 16-go Rossijskogo Nacional'nogo Kongressa s mezhdunarodnym uchastiem “Professija i zdorov'e”. Vladivostok: NPO Association of Physicians and Specialists in Occupational Medicine (AMT);2021:173–6. (In Russ.). DOI: 10.31089/978-5-6042929-2-1-2021-1-173-176

8. Bessonov P.P., Bessonova N.G., Krivoshapkin B.A. The issues of risk factors of atrophic gastritis among residents of Yakutia. MEDICUS. 2019;2(26):22–8. (In Russ.).

9. Belkovets A.V., Kurilovich S.A., Maksimov V.N., Ragino Yu.I., Shcherbakova L.V., Alyoshkina A.V., et al. IL1В polymorphism is associated with an increased risk of gastric cancer in the population of Western Siberia. Experimental and Clinical Gastroenterology. 2017;9(145):10–7. (In Russ.).

10. Rusakov N.V., Bobrovnickiy I.P., German S.V., Rusakova E.V. Actual hygienic and epidemiological problems of helicobacteriosis. Hygiene and Sanitation. 2018;97(12):1179–83. (In Russ.). DOI: 10.18821/0016-9900-2018-97-12-1179-1183

11. Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I., et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in Russia: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI: 10.1111/hel.12924

12. Luzina E.V., Dutova A.A., Lazebnik L.B., Lareva N.V. Treatment of Helicobacter pylori infection in healthcare workers. Experimental and Clinical Gastroenterology. 2023;3:28–40. (In Russ.). DOI: 10.31146/1682-8658-ecg-211-3-28-40

13. Kheyre H., Morais S., Ferro A., Costa A.R., Norton P., Lunet N., et al. The occupational risk of Helicobacter pylori infection: A systematic review. Int Arch Occup Environ Health. 2018;91(6):657–74. DOI: 10.1007/s00420-018-1315-6

14. Mastromarino P., Conti C., Donato K., Strappini P.M., Cattaruzza M.S., Orsi G.B. Does hospital work constitute a risk factor for Helicobacter pylori infection? J Hosp Infect. 2005;60(3):261–8. DOI: 10.1016/j.jhin.2004.12.019

15. Bordin D.S., Plavnik R.G., Nevmerzhitsky V.I., Butorova L.I., Abdulkhakov R.A., Abdulkhakov S.R., et al. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to the ¹³C-urease breath test. Almanac of Clinical Medicine. 2018;46(1):40–9. (In Russ.). DOI: 10.18786/2072-0505-2018-46-1-40-49

16. Bakulina N.V., Simanenkov V.I., Bakulin I.G., Ilchishina T.A. Prevalence of Helicobacter pylori infection among physicians. Experimental and Clinical Gastroenterology. 2017;148(12):20–4. (In Russ.).

17. Peters C., Schablon A., Harling M., Wohlert C., Costa J.T., Nienhaus A. The occupational risk of Helicobacter pylori infection among gastroenterologists and their assistants. BMC Infect Dis. 2011;11:154. DOI: 10.1186/1471-2334-11-154

18. Makristathis A., Hirschl A.M., Mégraud F., Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter. 2019;24(Suppl 1):e12641. DOI: 10.1111/hel.12641

19. Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., et al.; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA. 2004;291(2):187–94. DOI: 10.1001/jama.291.2.187

20. Loor A., Dumitraşcu D.L. Helicobacter pylori infection, gastric cancer and Gastropanel. Rom J Intern Med. 2016;54(3):151–6. DOI: 10.1515/rjim-2016-0025

21. Syrjänen K., Eskelinen M., Peetsalu A., Sillakivi T., Sipponen P., Härkönen M., et al. GastroPanel® biomarker assay: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. A critical review. Anticancer Res. 2019;39(3):1091–104. DOI: 10.21873/anticanres.13218

22. Storskrubb T., Aro P., Ronkainen J., Sipponen P., Nyhlin H., Talley N.J., et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol. 2008;43(12):1448–55. DOI: 10.1080/00365520802273025

23. Roman L.D., Lukyanchuk R., Sablin O.A., Araslanova E.I., Eklund C., Hendolin P., et al. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg. Anticancer Res. 2016;36(8):4129–38.

24. Misiewicz J.J. The Sydney system: A new classification of gastritis. Introduction. J Gastroenterol Hepatol. 1991;6(3):207–8. DOI: 10.1111/j.1440-1746.1991.tb01467.x

25. Saka A., Yagi K., Nimura S. OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy. Dig Endosc. 2015;27(7):734–41. DOI: 10.1111/den.12483

26. Strickland R.G., Mackay I.R. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis. 1973;5(18):426–40. DOI: 10.1007/BF01071995

27. Kimura K., Satoh K., Ido K., Taniguchi Y., Takimoto T., Takemoto T. Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl. 1996;214:17–20; discussion: 21–3. DOI: 10.3109/00365529609094509

28. Song J.H., Kim S.G., Jin E.H., Lim J.H., Yang S.Y. Risk factors for gastric tumorigenesis in underlying gastric mucosal atrophy. Gut Liver. 2017;11(5):612–9. DOI: 10.5009/gnl16488

29. Rugge M., Sugano K., Sacch D., Sbaraglia M., Malfertheiner P. Gastritis: An update in 2020. Curr Treat Options Gastro. 2020;3(18):488–503. DOI: 10.1007/s11938-020-00298-8

30. Hooi J.K.Y., Lai W.Y., Ng W.K., Suen M.M.Y., Underwood F.E., Tanyingoh D., et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9. DOI: 10.1053/j.gastro.2017.04.022

31. Evsyutina Yu.V. Eradication of H. pylori: A modern look at an old problem. RMJ. 2016;11:673–7. (In Russ.).

32. Syrjänen K. A panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res. 2016;36(10):5133–44. DOI: 10.21873/anticanres.11083